Range Cancer Therapeutics ETF Rating → If you have $2,500 bucks… check this out (From DTI) (Ad) Free CNCR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share RatingsStock AnalysisDividendHeadlinesHoldingsRatingsShort InterestSocial MediaStock AnalysisDividendHeadlinesHoldingsRatingsShort InterestSocial Media Range Cancer Therapeutics ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CNCR Aggregate RatingModerate Buy2.70Holdings in CNCR have an aggregate rating of Moderate Buy based on 355 analyst ratings issued in the past year covering 50 companies (70.9% of the portfolio).CNCR Aggregate Price Target$34.32138.49% UpsideHigh Prediction$47.29Average Prediction$34.32Low Prediction$23.80Holdings in CNCR have an aggregate price target of $34.32 and a range of $23.80 to $47.29 covering 50 companies (70.9% of the portfolio).CNCR Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy17 Buy rating(s)Moderate Buy22 Moderate Buy rating(s)Hold10 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Range Cancer Therapeutics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 50 CNCR Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings2.78%GERNGeron$3.79+6.5%3 of 5 stars3.00$5.33 40.7%3Upcoming EarningsShort Interest ↑2.54%ACRVAcrivon Therapeutics$8.46-0.1%4 of 5 stars3.00$22.63 167.4%8Analyst ReportNews Coverage2.20%ELVNEnliven Therapeutics$17.18+2.4%2 of 5 stars3.00$34.00 97.9%1Short Interest ↑1.82%JANXJanux Therapeutics$47.39+0.6%4 of 5 stars3.00$61.33 29.4%7Positive News1.75%NUVBNuvation Bio$2.68+2.3%3 of 5 stars3.00$6.60 146.3%5Upcoming Earnings1.67%TSVT2seventy bio$4.26-0.9%4 of 5 stars2.38$13.17 209.4%8Upcoming Earnings1.54%RVMDRevolution Medicines$35.96+1.8%4 of 5 stars3.10$41.20 14.6%10Positive News1.50%PRLDPrelude Therapeutics$4.07+0.7%3 of 5 stars1.67$5.25 29.0%31.48%LYELLyell Immunopharma$2.17-1.4%1 of 5 stars2.50$5.50 153.5%2Upcoming Earnings1.45%ACETAdicet Bio$1.68-7.2%2 of 5 stars2.63$12.83 663.9%8Analyst Report1.42%NRIXNurix Therapeutics$12.361 of 5 stars2.83$21.33 72.6%61.41%MRKMerck & Co., Inc.$131.20+0.4%5 of 5 stars2.58$131.33 0.1%12Earnings ReportAnalyst ReportAnalyst RevisionNews Coverage1.41%ITOSiTeos Therapeutics$10.80+1.9%1 of 5 stars3.00$30.33 180.9%3Positive News1.41%MGNXMacroGenics$14.56+1.3%4 of 5 stars2.89$18.00 23.6%9Analyst ReportShort Interest ↑News Coverage1.40%DAWNDay One Biopharmaceuticals$14.92+12.9%3 of 5 stars2.86$39.33 163.6%7Analyst ReportAnalyst RevisionNews CoverageHigh Trading Volume1.39%CGEMCullinan Oncology$25.30+31.4%3 of 5 stars3.00$28.75 13.6%6Short Interest ↑High Trading Volume1.37%YMABY-mAbs Therapeutics$14.71-0.9%1 of 5 stars2.33$16.57 12.7%6News Coverage1.37%EXELExelixis$23.70+0.7%5 of 5 stars2.60$26.29 10.9%15Upcoming EarningsShort Interest ↑Analyst RevisionNews Coverage1.36%FHTXFoghorn Therapeutics$5.49+5.0%1 of 5 stars2.67$14.50 164.1%31.36%MORMorphoSys$18.04-0.5%1 of 5 stars2.38$11.78 -34.7%8Upcoming Earnings1.36%IBRXImmunityBio$7.35+43.8%0 of 5 stars2.00$5.00 -32.0%1Options VolumeNews CoverageHigh Trading Volume1.35%HCMHUTCHMED$18.16-4.4%2 of 5 stars2.75$29.70 63.5%4News Coverage1.35%INBXInhibrx$34.06-0.1%1 of 5 stars2.00$27.00 -20.7%21.35%GLUEMonte Rosa Therapeutics$5.33-2.2%1 of 5 stars2.67$11.00 106.4%3Short Interest ↑Negative News1.34%STROSutro Biopharma$3.425 of 5 stars3.00$12.57 267.6%71.34%BPMCBlueprint Medicines$93.00+2.5%1 of 5 stars2.50$91.57 -1.5%14Upcoming EarningsAnalyst ReportNews CoverageGap Up1.32%IPHAInnate Pharma$2.46+2.5%1 of 5 stars3.00$9.75 296.3%1Short Interest ↑Gap Down1.32%GMABGenmab A/S$28.15+2.5%3 of 5 stars2.38$48.50 72.3%13Upcoming EarningsShort Interest ↑Gap Up1.32%AURAAura Biosciences$7.22+2.0%1 of 5 stars3.00$21.00 190.9%31.32%RAPTRAPT Therapeutics$8.10+3.8%4 of 5 stars2.50$25.67 216.9%121.31%SDGRSchrödinger$23.97+2.7%3 of 5 stars2.67$43.50 81.5%9Upcoming Earnings1.30%BCYCBicycle Therapeutics$22.73+0.9%2 of 5 stars2.86$46.86 106.1%7Upcoming EarningsShort Interest ↑1.29%PGENPrecigen$1.41+0.7%4 of 5 stars2.33$10.00 609.2%3News Coverage1.28%SNDXSyndax Pharmaceuticals$21.06+2.4%4 of 5 stars2.90$34.42 63.4%10Analyst Report1.27%DCPHDeciphera Pharmaceuticals$14.65+3.3%4 of 5 stars2.80$23.00 57.0%5Upcoming EarningsShort Interest ↓News Coverage1.27%REGNRegeneron Pharmaceuticals$883.20-0.8%4 of 5 stars2.70$977.77 10.7%20Upcoming EarningsAnalyst ReportAnalyst RevisionNews Coverage1.26%VORVor Biopharma$1.69-0.6%3 of 5 stars3.00$13.50 698.8%5Analyst Report1.26%ERASErasca$1.89+0.5%2 of 5 stars2.80$7.83 314.5%5Short Interest ↑1.26%BNTXBioNTech$87.21+0.6%4 of 5 stars2.30$120.40 38.1%10News Coverage1.25%IDYAIDEAYA Biosciences$39.94+3.4%3 of 5 stars3.00$46.60 16.7%121.25%BMYBristol-Myers Squibb$44.85+0.3%5 of 5 stars2.11$60.71 35.4%19Earnings ReportAnalyst ReportAnalyst RevisionNews Coverage1.24%ZNTLZentalis Pharmaceuticals$11.06+0.7%1 of 5 stars2.57$38.57 248.7%7Positive News1.23%APLMApollomics$0.45-4.3%1 of 5 stars3.00$5.00 1,011.1%1Short Interest ↑Gap Down1.23%IGMSIGM Biosciences$9.40+22.9%4 of 5 stars2.50$17.44 85.6%81.23%MRUSMerus$45.04+0.2%2 of 5 stars3.00$56.33 25.1%11Upcoming EarningsAnalyst RevisionNews Coverage1.21%IMCRImmunocore$58.46+0.8%3 of 5 stars2.85$81.50 39.4%13Analyst ReportShort Interest ↓News Coverage1.19%SWTXSpringWorks Therapeutics$45.53+3.0%3 of 5 stars3.00$68.00 49.4%6Upcoming EarningsNews Coverage1.18%IMTXImmatics$10.01+2.4%0 of 5 stars3.0011.18%RCUSArcus Biosciences$15.55+5.6%3 of 5 stars2.88$41.25 165.3%8Short Interest ↓1.17%DNAGinkgo Bioworks$0.86+10.3%1 of 5 stars2.00$2.20 155.8%5High Trading Volume This page (NASDAQ:CNCR) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithProtect Your Bank Account Before It’s Too LateWeiss RatingsBiden out June 13; Kamala won’t replace him?Paradigm PressThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
